FBR Capital Cuts Price Target on Athenahealth (ATHN) Following 2Q Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Deutsche Bank Downgrades athenahealth (ATHN) to Hold
July 22, 2016 6:58 AM EDTDeutsche Bank downgraded athenahealth (NASDAQ: ATHN) from Buy to Hold with a price target of $147.00 (from $165.00). Analyst George Hill pointed out disturbing underlying performance metrics.
"Athena reported concerning Q2 results after market close, where the revenue and earnings miss was among the... More
After-Hours Stock Movers 07/21 (PBYI) (EYES) (PFPT) Higher; (SKX) (ATHN) (P) Lower (more...)
July 21, 2016 5:59 PM EDTToday's After-Hours Movers
Puma Biotechnology, Inc. (NYSE: PBYI) 18.8% HIGHER; submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate PB272 (neratinib) for the extended adjuvant treatment of patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab (Herceptin®)-based therapy. Also, announced updated results from the Phase III clinical trial of Pumas investigational drug PB272 (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer (ExteNET trial). The ExteNET trial is a... More
UPDATE: Athenahealth (ATHN) Misses Q2 EPS by 8c, COO to Step Down at Year-End
July 21, 2016 4:06 PM EDT(Updated - July 25, 2016 10:31 AM EDT)
(Update corrects headline to say COO to step down, not CEO)
Athenahealth (NASDAQ: ATHN) reported Q2 EPS of $0.34, $0.08 worse than the analyst estimate of $0.42. Revenue for the quarter came in at $261.9 million versus the consensus estimate of $274.07... More
